An increased or stable sPD-1 level independently correlated with longer PFS in two cycles of nivolumab-treated metastatic NSCLC patients, suggesting sPD-1 as a predictive biomarker of response to ICI treatment in patients with lung cancer [51, 52]. The gene discussed is HOXD13; the disease is lung cancer.